Matthew J. Hamilton is a partner in the Litigation Department of Pepper Hamilton LLP and a member of the firm’s Health Effects Litigation Practice Group. He has more than 17 years experience representing clients in complex pharmaceutical products liability and commercial litigation, with a primary emphasis on the defense of federal multidistrict litigation, coordinated state court actions, class actions and other complex matters. He is a member of the firm’s Technology and E-Discovery Committees.
Mr. Hamilton has represented and advised clients in products liability, toxic tort, consumer fraud, breach of contract, antitrust, labor, securities, bankruptcy, warranty, personal injury and premises liability claims. He has significant experience managing, directing and coordinating complex litigation through joint-defense groups and local counsel across jurisdictions. In addition to trial and pretrial practice in state and federal courts, he is experienced in prosecuting and defending appeals in the appellate courts of Pennsylvania, federal circuit courts and the U.S. Supreme Court.
Mr. Hamilton has managed and directed large-scale electronic discovery in complex, multiparty litigation, and advises clients on electronic discovery issues, large-scale document review and production, and the development and management of case management databases.
Recent engagements include representing:
- a pharmaceutical manufacturer in nationwide, multidistrict and coordinated state court litigation involving an injectable Type II diabetes medicine
- a pharmaceutical manufacturer in nationwide, multidistrict and international products liability litigation involving a Type II diabetes medicine
- a pharmaceutical manufacturer in nationwide, multidistrict and international products liability litigation involving an anti-psychotic medicine
- representation of a medical device manufacturer in a products liability action involving allegations of serious personal injury due to device breakage
- a pharmaceutical manufacturer in product liability litigation involving allegations that a preservative in childhood vaccines caused developmental delays and other injuries
- a multinational chemical corporation and its foreign parent in complex, multiparty federal multidistrict antitrust action challenging its pricing of automotive refinishing paint
- an energy company in a multidistrict federal antitrust action challenging salary information exchange within the petrochemical industry
- a multinational chemical corporation in consumer class actions challenging the pricing of vitamin products as anticompetitive
- a bankruptcy creditors’ committee and prosecution of securities, fraud and breach of fiduciary claims.